Middle East and Africa Anticoagulant Reversal Drug Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product; End User

The anticoagulant reversal drug market in Middle East and Africa is expected to grow from US$ 34.5 million in 2019 to US$ 75.4 million by 2027; it is estimated to grow at a CAGR of 10.9% from 2019 to 2027. Oral anticoagulants are widely used drugs and are highly effective in preventing thromboembolism among AFib patients. However, the use of anticoagulants may lead to bleeding in AFib patients; thus, anticoagulant reversal drugs are used to prevent bleeding. The anticoagulant reversal drugs play an important role in managing and reducing blood loss by reversing the effect of the anticoagulant drug. A study was conducted in the Arabian Gulf, including Kuwait, the UAE, and Qatar, in 2016; the study group included subjects above the age of 18 from 64 health centers. The prevalence of peripheral vascular disease (PVD) was found to be 13.5% in the UAE population. Thus, such high prevalence of atrial fibrillation favors the growth of the anticoagulant reversal drug market in Middle East and Africa.

Based on product, the Middle East and Africa anticoagulant reversal drugs market is segmented into prothrombin complex concentrates, vitamin K, AndeXXa, protamine, idarucizumab, and tranexamic acid. In 2019, the vitamin K segment accounted for the largest market share. It is a reliable and fast alternative to fresh frozen plasma to control excessive bleeding as it has properties to reverse the effects of oral anticoagulant treatments, which contributes to the wide acceptance for this product. On the other hand, the market for AndeXXa is expected to grow at the fastest CAGR during the forecast period.

The Middle East and Africa includes countries such as South Africa, the UAE, and Saudi Arabia. These countries have also registered a significant number of positive novel coronavirus cases. The Middle East and Africa have a developing healthcare sector. The countries in these regions are highly dependent on medical devices and pharmaceutical products imported from developed countries from other regions. Therefore, governments in these countries find it challenging to procure anticoagulant reversal drugs. The COVID–19 has a remarkable impact on the heart. In many of the hospitals, general surgical procedures are being delayed, to prioritize the COVID–19 patients. Therefore, the lowered number of surgical procedures has led to the lowered need of anticoagulant reversal drugs that are used to reduce the excess blood loss during operations. However, as the crisis continues and government enforces relaxations on importing these drugs, the anticoagulant reversal drugs market players are expected to witness significant growth in the number of orders in the coming months.

The Middle East and Africa anticoagulant reversal drug market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining overview and forecast for the Middle East and Africa anticoagulant reversal drug market with respect to all the segments pertaining to the region. Also, multiple primary interviews have been conducted with industry participants and commentators to validate the data, as well as to gain more analytical insights into the topic. The participants of this process include industry expert such as VPs, business development managers, market intelligence managers, and national sales managers - along with external consultants such as valuation experts, research analysts, and key opinion leaders - specializing in the Middle East and Africa anticoagulant reversal drug market. Boehringer Ingelheim International GmbH, Pfizer Inc, Octapharma AG, Fresenius Kabi AG, Alexion Pharmaceuticals, Inc. (Portola Pharmaceuticals), CSL Limited, and Grifols, S.A. are among the players operating in the market in this region.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East and Africa anticoagulant reversal drug market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the Middle East and Africa anticoagulant reversal drug market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth Middle East and Africa market trends and outlook coupled with the factors driving the anticoagulant reversal drug market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution